Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een onderzoek naar JNJ-90189892 voor recidiverende of refractaire acute myeloïde leukemie of myelodysplastische neoplasmata

2 november 2026 bijgewerkt door: Janssen Research & Development, LLC

Een fase 1, first-in-human, dosis-escalatiestudie van JNJ-90189892 voor recidiverende of refractaire acute myeloïde leukemie of myelodysplastische neoplasmata

The purpose of Part 1 (Dose Escalation) of the study is to assess the effective dose (recommended Phase 2 dose[s] [RP2Ds]) that can be safely administered, and dosing regimens of JNJ-90189892 in participants with relapsed or refractory (R/R) acute myeloid leukemia (AML) or R/R higher-risk type of myelodysplastic neoplasms (MDS [type of cancer of the blood and bone marrow, which does not respond to treatment or comes back after treatment]). The purpose of Part 2 (Cohort Expansion) is to further assess the safety, tolerability and efficacy in participants with R/R AML or higher-risk types of MDS at the RP2D regimen(s). The purpose of Part 3 and 4 is to assess the effective dose (recommended Phase 2 combination dose [RP2CD]) that can be safely administered, and dosing regimens of JNJ-90189892 in combination with azacitadine (AZA) + venetoclax (VEN) in participants with R/R AML (part 3) and newly diagnosed (ND) AML (part 4).

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Werkelijk)

85

Fase

  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Concord, Australië, 2139
        • Concord Hospital
      • Melbourne, Australië, 3000
        • Peter MacCallum Cancer Centre
      • Nedlands, Australië, 6009
        • Sir Charles Gairdner Hospital
      • Marseille, Frankrijk, 13273
        • Institut Paoli-Calmettes
      • Strasbourg, Frankrijk, 67200
        • CHRU de Strasbourg - Hopital de Hautepierre
      • Toulouse, Frankrijk, 31100
        • Institut Claudius Regaud
      • Madrid, Spanje, 28040
        • Hosp Univ Fund Jimenez Diaz
      • Pamplona, Spanje, 31008
        • Clinica Univ. de Navarra
      • Seville, Spanje, 41013
        • Hospital Universitario Virgen Rocio

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • A. For Parts 1, 2, and 3: Have a diagnosis, per the world health organization (WHO) 2022 criteria, of (a) Parts 1, 2, and 3: Acute myeloid leukemia (AML) or (b) Parts 1 and 2: Moderate high, high, or very high-risk myelodysplastic neoplasms (MDS) per Molecular International Prognostic Scoring System (IPSS-M); B. For Part 4 only: Previously untreated acute myeloid leukemia (AML) per the WHO 2022 criteria
  • Body weight that is greater than or equals to (>=) 40 kg
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
  • Have adequate renal function defined as Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Estimated Glomerular Filtration Rate (eGFR) >=40 milligrams per minute (mL/min) computed with the calculator on the national kidney foundation website
  • Participants must have laboratory parameters in the required range

Exclusion Criteria:

  • Has a medical history of clinically significant pulmonary compromise, particularly the current need for supplemental oxygen use to maintain adequate oxygenation
  • Has evidence of uncontrolled systemic viral, bacterial, or fungal infection. Antimicrobial prophylaxis is permitted
  • All participants- Has known allergies, hypersensitivity, or intolerance to JNJ-90189892 or its excipients; Parts 3 and 4- Has known allergies, hypersensitivity, or intolerance to venetoclax (VEN), azacitadine (AZA), or their excipients
  • Had major surgery or had significant traumatic injury within 14 days of planned first dose of JNJ-90189892
  • Had a prior or concurrent second malignancy with natural history or treatment likely to interfere with any study endpoints of safety or the efficacy of the study treatment
  • Has known active central nervous system involvement

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Sequentiële toewijzing
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: JNJ-90189892: Monotherapy

Participants will receive JNJ-90189892 in Part 1 (Dose escalation) of the study and the dose levels will be escalated sequentially based on the decisions of the study evaluation team (SET) until the recommended phase 2 dose (RP2D) has been identified. Participants in Part 2 (Dose expansion) will receive JNJ-90189892 at the RP2D determined in Part 1.

JNJ-90189892 will be administered.

Experimenteel: JNJ-90189892: In Combination with Azacitadine (AZA)+ Venetoclax (VEN)

Participants with relapsed or refractory (R/R) acute myeloid leukemia (AML) in Part 3 will receive JNJ-90189892+ AZA+VEN to determine the recommended Phase 2 combination dose (RP2CD). The starting JNJ-90189892 dose regimen in Part 3 will be at least 1 dose level below the highest dose level cleared in Part 1 as determined by the SET. In Part 4 participants with newly diagnosed (ND) AML will receive JNJ-90189892+ AZA+VEN starting from the JNJ-90189892 dose level determined safe in Part 3 by the SET.

JNJ-90189892 will be administered.

AZA will be administered.

VEN will be administered.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number of Participants with Adverse events (AEs) by Severity
Tijdsspanne: From screening untill 30 days after last dose of study drug (that is approximately 2.5 years)

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.

From screening untill 30 days after last dose of study drug (that is approximately 2.5 years)
Part 1: Number of Participants with Dose-Limiting Toxicity (DLTs)
Tijdsspanne: At least 14 days

DLT is defined as any toxicity that requires discontinuation of treatment, any Grade 5 toxicity; Non-hematologic toxicity (Grade 3 or 4) and Hematologic toxicity.

At least 14 days

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Serum Concentration of JNJ-90189892
Tijdsspanne: Up to approximately 2.5 years

Serum samples will be analyzed to determine concentrations of JNJ-90189892.

Up to approximately 2.5 years
Area Under the Curve Over a Dosing Interval (AUC tau) of JNJ-90189892
Tijdsspanne: Up to approximately 2.5 years

AUC tau is the total observed plasma concentration of JNJ-90189892 in the body during the time between doses. AUCtau of JNJ-90189892 will be reported.

Up to approximately 2.5 years
Maximum Observed Plasma Concentration (Cmax) of JNJ-90189892
Tijdsspanne: Up to approximately 2.5 years

Cmax is the maximum observed plasma concentration of JNJ-90189892. Cmax of JNJ-90189892 will be reported.

Up to approximately 2.5 years
Minimum Observed Plasma Concentration (Cmin) of JNJ-90189892
Tijdsspanne: Up to approximately 2.5 years

Cmin is the minimum observed plasma concentration of JNJ-90189892. Cmin of JNJ-90189892 will be reported.

Up to approximately 2.5 years
Number of Participants with Presence of Anti-JNJ-90189892 Antibodies
Tijdsspanne: Up to approximately 2.5 years

Participants with presence of anti-JNJ-90189892 antibodies will be reported.

Up to approximately 2.5 years
Complete Response (CR) in Acute Myeloid Leukemia (AML)
Tijdsspanne: Up to approximately 2.5 years

CR is achieved when a participant has a best response of CR (including complete response with partial hematologic recovery [CRh] or complete response with incomplete hematologic recovery [CRi]) according to the European Leukemia Network (ENL) 2022 criteria.

Up to approximately 2.5 years
Overall Response (OR) in Myelodysplastic Neoplasms (MDS)
Tijdsspanne: Up to approximately 2.5 years

OR is achieved when a participant with MDS has a CR (any type, that is CRh or complete response with limited count recovery [CRL]), partial response (PR), or hematologic improvement (HI) according to the International Working Group (IWG) 2023 criteria.

Up to approximately 2.5 years
Complete Response in MDS
Tijdsspanne: Up to approximately 2.5 years

CR is achieved when a participant has a best response of CR (including CRh/CRL) according to the IWG 2023 criteria.

Up to approximately 2.5 years
Duration of Response (DOR)
Tijdsspanne: Up to approximately 2.5 years

DOR is defined for responsders only, as time from date of initial documentation of a response to the first documented evidence of no reponse, disease progression, relapse, initation of a new systemic anti-cancer therapy (besides hematopoietic stem cell transplant [HSCT]), or death, whichever comes first.

Up to approximately 2.5 years
Time to Response (TTR)
Tijdsspanne: Up to approximately 2.5 years

TTR is defined for responders, as the time from the first dose of study drug to first qualifying response.

Up to approximately 2.5 years
Number of Participants Achieving Transfusion Independence
Tijdsspanne: Up to approximately 2.5 years

Transfusion independence is defined as the absence of red blood cell (RBC) and platelet transfusions for 8 weeks or longer after starting study treatment for participants with AML and 16 weeks or longer for participants with MDS.

Up to approximately 2.5 years
Part 4 Only: Overall Survival (OS)
Tijdsspanne: Up to approximately 2.5 years

OS is defined as the time from the date of first dose of study treatment to the date of death due to any cause.

Up to approximately 2.5 years
Part 4 Only: Event-Free Survival (EFS)
Tijdsspanne: Up to approximately 2.5 years

EFS is defined as the time from the date of first dose of study treatment to the date of first documented evidence of treatment failure, relapse or death due to any cause, whichever occurs first.

Up to approximately 2.5 years

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

21 maart 2025

Primaire voltooiing (Geschat)

5 augustus 2027

Studie voltooiing (Geschat)

9 februari 2028

Studieregistratiedata

Eerst ingediend

18 oktober 2024

Eerst ingediend dat voldeed aan de QC-criteria

18 oktober 2024

Eerst geplaatst (Werkelijk)

21 oktober 2024

Updates van studierecords

Laatste update geplaatst (Werkelijk)

3 november 2026

Laatste update ingediend die voldeed aan QC-criteria

2 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • 90189892AML1001
  • 2024-514341-10-00 (Register-ID: EUCT number)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Ja

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren